{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-054818","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2023-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.362881+00:00","generated_at":"2026-06-13T12:40:45.519488+00:00","sec_items":["1.01","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intensity Therapeutics upsized IPO priced at $5.00/share; gross proceeds $19.5M","bullets":["Sold 3,900,000 shares at $5.00/share for gross proceeds of $19.5M; net proceeds of $16.2M.","Underwriters have 45-day option to purchase up to 585,000 additional shares at same price.","Common stock began trading on Nasdaq Capital Market on June 30, 2023 under ticker 'INTS'.","Net proceeds to fund clinical trials, operations, product development, and working capital.","Amended and restated charter and bylaws effective upon closing of IPO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-054818","json":"https://secwatch.observer/filing/0001213900-23-054818.json","markdown":"https://secwatch.observer/filing/0001213900-23-054818.md","text":"https://secwatch.observer/filing/0001213900-23-054818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/ea181296-8k_intensity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:40:45.519488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26dd92c5ca9327137edcb0c8fad66faa59333477","claim":"INTENSITY THERAPEUTICS, INC.: Adopted amended and restated Bylaws effective upon closing of the Offering (effective 2023-07-05).","evidence_excerpt":"In connection with the closing of the Offering, effective as of July 5, 2023, the Company adopted amended and restated bylaws (the “ Amended and Restated Bylaws ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-05"}],"fact_type":"governance_change"},{"claim_id":"2b25fa98647cdb6f94639272d1aa39e815402a68","claim":"INTENSITY THERAPEUTICS, INC.: Filed Sixth Amended and Restated Certificate of Incorporation in connection with closing of the initial public offering (effective 2023-06-30).","evidence_excerpt":"In connection with the closing of the Offering, on June 30, 2023, the Company filed its Sixth Amended and Restated Certificate of Incorporation (the “ Sixth Amended and Restated Charter ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-30"}],"fact_type":"governance_change"},{"claim_id":"a123e13f061f2fecad18c5f2b5f7606fa9771415","claim":"INTENSITY THERAPEUTICS, INC. entered into Underwriting Agreement with The Benchmark Company, LLC valued at Total gross proceeds of $19,500,000 from sale of 3,900,000 shares at $5.00 per share (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Intensity Therapeutics, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with The Benchmark Company, LLC, as representative of the underwriters named on Schedule 1 thereto (the “Representative ”) relating to the Company’s firm commitment underwritten initial public offering (the “ Offering ”) of common stock, par value $0.0001 per share (the “ Common Stock ”), which was registered under the Securities Act of 1933, as amended (the “ Securities Act ”) by the Company’s registration statement on Form S-1, as amended (File No. 333-260565) (the “ Registration Statement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023054818/0001213900-23-054818-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"The Benchmark Company, LLC"},{"label":"Value","value":"Total gross proceeds of $19,500,000 from sale of 3,900,000 shares at $5.00 per share"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}